Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event
NCT02877615
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
585
Enrollment
OTHER
Sponsor class
Conditions
Post Stroke Recovery
Interventions
DRUG:
S 44819 150 mg twice a day
DRUG:
S 44819 300 mg twice a day
DRUG:
Placebo
Sponsor
Institut de Recherches Internationales Servier
Collaborators
[object Object]